| Primary |
| Glaucoma |
46.9% |
| Hypertension |
16.3% |
| Drug Use For Unknown Indication |
8.2% |
| Open Angle Glaucoma |
6.1% |
| Ocular Hypertension |
4.1% |
| Product Used For Unknown Indication |
4.1% |
| Blood Parathyroid Hormone Increased |
2.0% |
| Brain Operation |
2.0% |
| Glaucoma Traumatic |
2.0% |
| Hyperparathyroidism |
2.0% |
| Intraocular Pressure Increased |
2.0% |
| Osteoarthritis |
2.0% |
| Vitamin Supplementation |
2.0% |
|
| Peripheral Coldness |
14.3% |
| Syncope |
10.7% |
| Idiopathic Thrombocytopenic Purpura |
7.1% |
| Systemic Lupus Erythematosus |
7.1% |
| Weight Increased |
7.1% |
| Asthma |
3.6% |
| Chronic Obstructive Pulmonary Disease |
3.6% |
| Eye Pain |
3.6% |
| Eye Pruritus |
3.6% |
| Fall |
3.6% |
| Maternal Drugs Affecting Foetus |
3.6% |
| Meningioma |
3.6% |
| Myasthenia Gravis |
3.6% |
| Nodal Arrhythmia |
3.6% |
| Oropharyngeal Blistering |
3.6% |
| Pneumonia |
3.6% |
| Pre-eclampsia |
3.6% |
| Sensory Disturbance |
3.6% |
| Sinus Bradycardia |
3.6% |
| Skin Ulcer |
3.6% |
|
| Secondary |
| Glaucoma |
25.7% |
| Hypertension |
17.9% |
| Open Angle Glaucoma |
13.6% |
| Product Used For Unknown Indication |
10.7% |
| Drug Use For Unknown Indication |
6.4% |
| Depression |
5.7% |
| Atrial Fibrillation |
4.3% |
| Hyperparathyroidism |
2.1% |
| Intraocular Pressure Increased |
2.1% |
| Ocular Hypertension |
2.1% |
| Antiinflammatory Therapy |
1.4% |
| Benign Prostatic Hyperplasia |
1.4% |
| Headache |
1.4% |
| Cerebral Infarction |
0.7% |
| Dizziness |
0.7% |
| Essential Hypertension |
0.7% |
| Gastritis |
0.7% |
| Insomnia |
0.7% |
| Keratoconjunctivitis Sicca |
0.7% |
| Neck Pain |
0.7% |
|
| Intraocular Pressure Increased |
14.3% |
| Peripheral Coldness |
11.4% |
| Thrombocytopenia |
11.4% |
| Renal Failure |
8.6% |
| Weight Increased |
8.6% |
| Fall |
5.7% |
| Corneal Erosion |
2.9% |
| Dysgeusia |
2.9% |
| Epistaxis |
2.9% |
| Hyperprolactinaemia |
2.9% |
| Maternal Drugs Affecting Foetus |
2.9% |
| Meningioma |
2.9% |
| Myocardial Infarction |
2.9% |
| Night Sweats |
2.9% |
| Nodal Arrhythmia |
2.9% |
| Pre-eclampsia |
2.9% |
| Punctate Keratitis |
2.9% |
| Renal Impairment |
2.9% |
| Sensory Disturbance |
2.9% |
| Sleep Disorder |
2.9% |
|
| Concomitant |
| Hypertension |
15.5% |
| Product Used For Unknown Indication |
15.3% |
| Glaucoma |
11.9% |
| Drug Use For Unknown Indication |
10.4% |
| Pneumonia |
5.1% |
| Ocular Hypertension |
4.9% |
| Gastritis |
3.8% |
| Osteoporosis |
3.8% |
| Rheumatoid Arthritis |
3.6% |
| Open Angle Glaucoma |
3.1% |
| Type 2 Diabetes Mellitus |
3.1% |
| Angina Pectoris |
2.5% |
| Gastric Ulcer |
2.5% |
| Parkinson's Disease |
2.5% |
| Insomnia |
2.1% |
| Postoperative Care |
2.1% |
| Cardiac Failure |
2.0% |
| Prophylaxis |
2.0% |
| Reflux Oesophagitis |
2.0% |
| Headache |
1.8% |
|
| Visual Acuity Reduced |
12.0% |
| Conjunctival Hyperaemia |
10.7% |
| Intraocular Pressure Increased |
8.0% |
| Shock |
8.0% |
| Cataract |
6.7% |
| Pulmonary Oedema |
5.3% |
| Blood Pressure Increased |
4.0% |
| Infusion Related Reaction |
4.0% |
| Lung Disorder |
4.0% |
| Multiple Drug Overdose |
4.0% |
| Pyrexia |
4.0% |
| Renal Failure |
4.0% |
| Respiratory Arrest |
4.0% |
| Rhabdomyolysis |
4.0% |
| Therapeutic Agent Toxicity |
4.0% |
| Anaphylactic Shock |
2.7% |
| C-reactive Protein Increased |
2.7% |
| Discomfort |
2.7% |
| Eosinophilia |
2.7% |
| Eyelash Thickening |
2.7% |
|
